Skip to main content
    A

    Alto Neuroscience, Inc. (ANRO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NYSE

    $27.14
    -2.40 (-8.12%)

    Market Cap: $1.18B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Alto Neuroscience, Inc. (ANRO) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    Alto Neuroscience reported revenue of $0 for the fiscal year ended Sep 30, 2025. That year, net income was -$63.24M, operating cash flow was -$51.77M and free cash flow was -$51.79M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$25.12M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Sep 2025, with an operating loss of $66.36M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Sep 2025$0N/AN/AN/AN/A
    Sep 2024$0N/AN/AN/AN/A
    Sep 2023$0N/AN/AN/AN/A
    Sep 2022$0-100.0%N/AN/AN/A
    Sep 2021$210.00KN/A31.0%-5741.0%-4374.8%
    Annual, fiscal years ended Sep 2021 to Sep 2025

    Income Statement

    In the fiscal year ended Sep 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021
    Revenue$0$0$0$0$210.00K
    Cost of revenue$661.00K$502.00K$373.00K$342.00K$145.00K
    Gross profit-$661.00K-$502.00K-$373.00K-$342.00K$65.00K
    Research and development$45.62M$47.00M$30.29M$23.69M$8.37M
    Operating income-$66.36M-$68.61M-$37.81M-$29.19M-$12.06M
    Net income-$63.24M-$61.43M-$36.30M-$27.71M-$9.19M
    EBITDA-$60.11M-$62.30M-$34.56M-$27.37M-$9.04M
    Fiscal years ended Sep 2021 to Sep 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$394.00K$0$0$0$372.00K
    Gross profitN/AN/A-$184.00K-$157.00K-$164.00K-$100.00K-$171.00K-$170.00K-$200.00K-$100.00K-$97.00K-$92.00K
    Operating income-$27.23M-$29.13M-$27.14M$115.67M-$14.95M-$18.68M-$15.68M-$17.00M-$18.89M-$18.34M-$14.39M-$11.77M
    Net income-$25.12M-$27.64M-$26.24M-$16.18M-$14.18M-$17.71M-$15.17M-$15.20M-$16.78M-$16.03M-$13.42M-$11.22M
    Last 12 quarters

    Balance Sheet

    As of Sep 2025, cash and equivalents exceeded total debt of $18.98M by $157.50M.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021
    Total assets$184.69M$177.54M$86.63M$50.85M$28.79M
    Current assets$177.72M$169.34M$85.39M$49.22M$27.68M
    Cash and equivalents$176.48M$168.23M$82.55M$48.34M$25.70M
    Total liabilities$33.55M$26.08M$158.30M$89.26M$41.27M
    Short-term debt$585.00K$870.00K$125.00K$283.00KN/A
    Long-term debt$18.40M$11.56M$9.86M$9.46MN/A
    Shareholder equity$151.14M$151.46M-$71.67M-$38.41M-$12.48M
    Fiscal years ended Sep 2021 to Sep 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$326.50M$254.07M$276.26M$184.69M$147.01M$157.88M$171.91M$177.54M$191.61M$197.36M$209.92M$86.63M
    Total liabilities$29.98M$34.82M$32.89M$33.55M$35.45M$34.47M$32.82M$26.08M$26.56M$17.58M$16.82M$158.30M
    Cash and equivalents$319.34M$243.73M$263.76M$176.48M$137.82M$147.59M$160.75M$168.23M$181.70M$193.12M$205.90M$82.55M
    Shareholder equity$296.53M$219.25M$243.37M$151.14M$111.56M$123.41M$139.10M$151.46M$165.05M$179.78M$193.10M-$71.67M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Sep 2025.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021
    Operating cash flow-$51.77M-$47.42M-$33.45M-$20.39M-$9.26M
    Capital expenditures$24.00K$2.08M$470.00K$732.00K$680.00K
    Free cash flow-$51.79M-$49.50M-$33.92M-$21.13M-$9.94M
    Investing cash flow-$24.00K-$2.08M-$470.00K-$732.00K-$680.00K
    Financing cash flow$60.08M$135.69M$68.13M$43.79M$31.69M
    Fiscal years ended Sep 2021 to Sep 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$20.76M-$19.76M-$27.09M-$11.52M-$9.92M-$13.78M-$16.56M-$13.02M-$11.73M-$11.69M-$10.98M-$11.52M
    Capital expenditures$0$0$556.00K$0$0$0$24.00K$506.00K$1.00M$340.00K$224.00K$352.00K
    Free cash flow-$20.76M-$19.76M-$27.65M-$11.52M-$9.92M-$13.78M-$16.58M-$13.53M-$12.73M-$12.03M-$11.21M-$11.88M
    Last 12 quarters

    Frequently Asked Questions About ANRO

    What is Alto Neuroscience's annual revenue?

    Alto Neuroscience reported revenue of $0 for the fiscal year ended Sep 30, 2025.

    Is Alto Neuroscience profitable?

    No. Alto Neuroscience reported net income of -$63.24M for the fiscal year ended Sep 30, 2025.

    How much free cash flow does ANRO generate?

    For the fiscal year ended Sep 30, 2025, operating cash flow of -$51.77M minus capital expenditures of $24.00K produced free cash flow of -$51.79M.

    How much debt does Alto Neuroscience have?

    The balance sheet dated Sep 30, 2025 reported long-term debt of $18.40M, short-term debt of $585.00K and cash and equivalents of $176.48M.